Hyundai Bioscience Co., Ltd. (048410.KQ)

29,200.00 +150.00 (+0.52%) At close: 03:30PM KST

Hyundai Bioscience Co., Ltd.

150, Bugahyeon-ro
3rd Floor Seodaemun-gu
Seoul 03759
South Korea
82 1 544 3194
https://www.hyundaibioscience.com

Sector(s): 
Industry: 
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Jong-Won Choi	Joint Chief Executive Officer	N/A	N/A	1967
Ho-Suk Chon	Joint Chief Executive Officer	N/A	N/A	1958
Yeong-Jin Kim	President	N/A	N/A	1970
Seok-Yong Choi	Chief Operating Officer and Senior Managing Director	N/A	N/A	1962

Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in KRW.

Description

Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19. The company was founded in 2000 and is based in Seoul, South Korea.

Corporate Governance

Hyundai Bioscience Co., Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.